RI
VRTX icon

Ridgewood Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

Ridgewood Investments’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-16
Closed -$7.38K – 806
2024
Q2 		$7.38K Buy
+16
New +$6.95K ﹤0.01% 542
2023
Q3 		– Sell
-19
Closed -$6.68K – 758
2023
Q2 		$6.68K Hold
19
– – ﹤0.01% 554
2023
Q1 		$5.98K Buy
+19
New +$5.7K ﹤0.01% 576

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Ridgewood Investments's VRTX Position: Q3 2024 in Review

Ridgewood Investments sold out of Vertex Pharmaceuticals (VRTX) in Q3 2024, closing a stake of 16 shares — an estimated $7.38K sold.

Ridgewood Investments first reported a position in VRTX in Q1 2023 and held it in 3 quarters. The position peaked at $7.38K in Q2 2024. 1,548 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.

  • Ridgewood Investments reported no remaining Vertex Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Ridgewood Investments sold 16 Vertex Pharmaceuticals shares in Q3 2024, an estimated $7.38K.
  • Ridgewood Investments first reported a position in Vertex Pharmaceuticals in Q1 2023 and held it in 3 quarters.
  • Ridgewood Investments's Vertex Pharmaceuticals position peaked at $7.38K in Q2 2024.
  • 1,548 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.

Based on Ridgewood Investments's 13F filing for Q3 2024, filed 4 Oct 2024.